CoronaVac / Sinovac, Bio Farma Indonesia - LARVOL DELTA

The resident gut microbiome modulates the effect of synbiotics on the immunogenicity after SARS-COV-2 vaccination in elderly and diabetes patients. (PubMed, NPJ Biofilms Microbiomes) - "Importantly, SIM01 strain engraftment assessed by StrainPhlAn (A metagenomic strain-level population genomics tool) was associated with a higher fold change of three bifidobacterial species and could be predicted based on the baseline gut microbiome. Therefore, the resident gut microbiome affected the SIM01 engraftment, which was associated with the immunogenicity of SARS-CoV-2 BNT162b2 vaccines."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Respiratory Diseases

Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia. (PubMed, Vaccine) - "During the COVID-19 pandemic, Malaysia adopted heterologous vaccine booster strategies using BNT162b2 (Pfizer), CoronaVac (Sinovac) and ChAdOx1 nCoV-19 (AstraZeneca) due to vaccine shortages...In individuals infected two years after booster vaccination, T cell responses increased in healthy participants but declined in KTRs despite strong antibody responses, suggesting immunosuppressive therapy may impair T cell activation. These findings highlight the need for comprehensive immune assessments to guide preventive strategies, especially for immunocompromised populations."

Journal • Infectious Disease • Novel Coronavirus Disease • Transplantation

Polymorphism in IFNλ Can Impact the Immune/Inflammatory Response to COVID-19 Vaccination in Older CMV-Seropositive Adults. (PubMed, Vaccines (Basel)) - "CMV-seropositivity in older adults who had Allele-1 could lead to an unbalanced systemic inflammatory state, which may impair their antibody response to COVID-19 vaccination compared to other volunteer groups."

Journal • Cytomegalovirus Infection • Infectious Disease • Inflammation • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8 • IFNB1 • IFNL3

Cross-neutralization effect of the third dose of inactivated COVID-19 vaccine against the SARS-CoV-2 variants. (PubMed, Expert Rev Vaccines) - "Among other variants, the GMFI against Omicron variants (BA.1, BA.4/5, BF.7) exceeded that for Beta and Delta, with the highest GMFI recorded for the BA.4/5 variant at 4.97 (95% CI: 3.08, 8.05). The necessity of the third booster dose lies in its ability to enhance the breadth of the immune response."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Clinical, epidemiological, and laboratory analysis of hospitalized and fatal COVID-19 cases in the first fully vaccinated municipality in Northeast Brazil. (PubMed, Rev Inst Med Trop Sao Paulo) - "Of these nine patients, 4 received anticoagulants and corticosteroids; 6, oxygen supplementation; 2, oseltamivir; and 3, empirical antibiotic for pneumonia. The mean interval between the last vaccine dose and hospitalization totaled 128 days (28-326; SD 137). These findings highlight incomplete vaccination, a prolonged interval since last doses, comorbidities, and advanced age as key factors associated with severe cases and deaths and emphasize the protective role of high vaccination coverage."

Journal • Cardiovascular • Cough • Diabetes • Hypertension • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases

Which type of vaccine is more beneficial for reducing the risk of deep vein thrombosis, CoronaVac, BNT162b2, or TURKOVAC? (PubMed, Sci Prog) - "Deep vein thrombosis was least common in patients who received only BNT162b2. Although the frequency of deep vein thrombosis was similar in the groups, we found that the lowest rate of deep vein thrombosis was in the group that received TURKOVAC after BNT162b2."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Novel Coronavirus Disease • Thrombosis • Venous Thromboembolism

Age and primary vaccination schedule impact humoral and cellular immunity with an inactivated SARS-CoV-2 vaccine. (PubMed, iScience) - "The 0-14 schedule produced equivalent cellular and neutralizing antibody responses between age groups, albeit at lower levels than the 0-28 schedule. Our data indicate that primary vaccination schedules can influence the humoral immune responses and memory T cell distribution between age groups."

Journal • Cognitive Disorders • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD4 • CD8

Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial. (PubMed, Vaccine) - P3 | "IgG-N titres peaked in the 13th week and declined. The homologous booster enhanced significantly the immune response compared to the heterologous one (Pfizer)."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety of COVID-19 revaccination in patients with prior hypersensitivity reactions: a retrospective study. (PubMed, Trop Dis Travel Med Vaccines) - "In this study, COVID-19 revaccination in patients with a history of COVID-19 vaccine-related HSRs was generally safe, with most patients tolerating it well. However, individuals with underlying allergic conditions, particularly allergic rhinitis, exhibited a higher incidence of mild reactions, especially following revaccination with an inactivated vaccine."

Journal • Retrospective data • Allergic Rhinitis • Allergy • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease

Neutralizing antibody response to different COVID-19 vaccines in Brazil: the impact of previous infection and booster doses. (PubMed, Front Immunol) - "In Brazil, three COVID-19 vaccines were among the first widely used (CoronaVac, ChAdOx1, and BNT162b2), which aimed to induce neutralizing antibodies (NAbs) against the original SARS-CoV-2 strain...Our findings provide valuable population-based comparison of NAb levels elicited by different vaccines following primary inoculation and booster doses. Notably, the mRNA vaccine exhibited a strong primary and initial booster NAb response against SARS-CoV-2."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Effectiveness of CoronaVac primary series with and without booster against hospitalized COVID-19 during the omicron-predominant epidemic wave in the Philippines: a test-negative case-control study. (PubMed, Expert Rev Vaccines) - "Two doses of CoronaVac offered moderate protection against severe COVID-19. Heterologous boosters significantly improved protection, especially against critical illness and death, supporting ongoing booster campaigns after inactivated vaccine priming."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immune memory reactivation and T cell dynamics following 12-month homologous CoronaVac booster: a longitudinal cohort study. (PubMed, Front Immunol) - "Delayed homologous CoronaVac booster immunization effectively reactivates immune memory, facilitated by Th1 polarization and transient T cell activation, which do not result in T cell exhaustion. These findings suggest the potential application of long-interval immunization strategies against COVID-19."

IO biomarker • Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CD69 • CTLA4 • GATA3 • IFNG • IL4 • IL5 • PD-1

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial. (PubMed, Vaccine) - "CoronaVac demonstrated moderate efficacy in preventing symptomatic COVID-19 and high efficacy against severe disease. While reactions were slightly more common in the vaccine group, they were generally mild and manageable."

Journal • Infectious Disease • Novel Coronavirus Disease • Pain • Respiratory Diseases

COVID-19 Vaccine Response in Allo-HSCT Recipients: Insights from a Real-World Prospective Cohort Study. (PubMed, Vaccines (Basel)) - " Allo-HSCT recipients (median age: 48 years) who received either the BNT162b2 or CoronaVac vaccines were included...The use of Ruxolitinib or Ibrutinib was associate with increased odds of low antibody response (OR: 38.39; 95% CI: 3.14-468.95; p = 0.004 **)... COVID-19 vaccination is safe and effective in Allo-HSCT recipients, with stronger responses especially following ≥3 vaccine doses. Patients receiving GVHD treatment or with hypogammaglobulinemia exhibited impaired responses, emphasizing the need for tailored vaccination strategies and close monitoring in this population."

Journal • Real-world evidence • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • Transplantation

Proteomic Profiling of Human Peripheral Blood Cell Targets of IgG Induced by SARS-CoV-2: Insights into Vaccine Safety. (PubMed, Vaccines (Basel)) - "Our study underscores the importance of distinguishing between the immune responses triggered by infection and vaccination and highlights the need for the continued monitoring of autoimmune responses in severe COVID-19 cases. Future research should focus on the long-term persistence and clinical relevance of these autoantibodies, particularly in individuals with pre-existing autoimmune conditions or genetic predispositions."

Journal • Immunology • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparison of SARS-CoV-2 IgG responses in hemodialysis patients and healthcare workers after COVID-19 vaccination. (PubMed, Front Immunol) - "While HCWs who received only CoronaVac showed lower antibody titers than those who received BNT162b2 or a heterologous schedule, this difference was not observed in HD patients. These results suggest that COVID-19 vaccination elicits a robust humoral immune response in the HD population, underscoring the benefit of vaccination in this high-risk group."

Clinical • Journal • Infectious Disease • Novel Coronavirus Disease • Renal Disease • Respiratory Diseases

Neutralizing antibody response to Omicron subvariants BA.1 and BA.5 in children and adolescents following the two-dose CoronaVac protocol (Immunita-002, Brazil): a 12-month longitudinal study. (PubMed, Front Immunol) - "The robust response highlights the vaccine's potential as a critical tool for reducing SARS-CoV-2 transmission and preventing severe disease, particularly in regions with limited access to updated vaccines. Further studies with larger cohorts are needed to validate these findings and inform vaccination strategies for immunoresistant variants."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A 20-month longitudinal study to evaluate humoral and cellular immunity after COVID-19 vaccines. (PubMed, Mem Inst Oswaldo Cruz) - "High antibody levels were maintained for up to six months following both homologous and heterologous vaccination. However, cellular immunity declined more markedly in the Sinovac-CoronaVac + Pfizer group, resulting in a higher proportion of non-responders. These findings underscore the importance of tailored booster strategies to sustain protective immunity against COVID-19."

Journal • Observational data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

The impact of vaccine booster doses on specific B- and T-lymphocyte dynamics in Thai healthcare personnel following COVID-19 vaccination. (PubMed, Sci Rep) - "A primary series of Sinovac COVID-19 vaccine (CoronaVac) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine successfully increased anti-spike antibodies, neutralizing antibodies, and T-lymphocytes, as was also observed following booster doses of Oxford-AstraZeneca or BNT162b2 (Pfizer-BioNTech) vaccine...Initial COVID-19 booster doses were essential for overall increases in the peak counts of antigen-specific B-lymphocytes, prior to minimal contraction phases occurred following additional boosters, while antigen-specific T-lymphocyte counts maintained a consistently high levels of immune response. The second, third, and fourth booster doses restored the levels of both B- and T-lymphocytes after the immune responses waned in a time-dependent manner."

Journal • Infectious Disease • Novel Coronavirus Disease • Oncology • Respiratory Diseases • IFNG • TNFA

Quantitative Immunoglobulin G and Interferon-Gamma Responses After Different Booster Strategies of CoronaVac and BNT162b2 Vaccines in Türkiye. (PubMed, Infect Dis Clin Microbiol) - "The median IgG and IFN-γ values were significantly higher in the younger participants compared to the older participants in Group 3. Our findings revealed that although homologous and heterologous boosting in inactivated vaccine-primed individuals provided effective humoral and cellular immunity, boosting with two doses of BNT162b2 should be prioritized since it exhibited a positive impact on both humoral and cellular immunity."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • IFNG

Evaluating the Humoral Immune Response to Sinovac-Coronavac in a Pediatric Patient with Propionic Acidemia: A Case Study. (PubMed, Turk Arch Pediatr) - No abstract available

Journal • Pediatrics

Safety comparison of mRNA, viral vector, and inactivated Covid-19 vaccines: incidence of adverse events following primary and booster doses among medical professionals in Malaysia. (PubMed, BMC Infect Dis) - "The incidence of adverse events following the first dose of the Covid-19 vaccine was highest among Vaxzevria recipients. Adverse events following Comirnaty vaccine increased gradually from primary to booster dose, whereas recipients with CoronaVac showed subsequent lesser adverse events following primary and booster doses."

Adverse events • Journal • Fatigue • Infectious Disease • Musculoskeletal Pain • Novel Coronavirus Disease • Pain

Immunogenicity and safety of CoronaVac vaccine in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up. (PubMed, Sci Rep) - "Adverse events recorded so far have been mild and transient, except for seven serious adverse events reported on VigiMed. The results indicate a robust and sustained immune response induced by CoronaVac in children and adolescents for up to six months, providing evidence to support the safety and immunogenicity of this effective immunizer."

Journal • P4 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative analysis of humoral immunity kinetics following three COVID-19 vaccines in a multi-ethnic cohort of medical students and healthcare professionals across Malaysia. (PubMed, Sci Rep) - "The objective of our study was to evaluate the time-dependent humoral immunity kinetics among multi-ethnic population of medical students and healthcare professionals across Malaysia following two doses of Comirnaty, Vaxzevria, and CoronaVac vaccines...Higher BMI, however, was associated with more robust humoral immune responses to Vaxzevria vaccine. Following immunisation, the Chinese and Indian populations might exhibit a stronger humoral immune response than the Malay population."

Clinical • Journal • Observational data • Infectious Disease • Novel Coronavirus Disease

A 22 month prospective assessment of neutralizing and IgG antibody levels against SARS-CoV-2 variants following homologous and heterologous BNT162b2 boosting. (PubMed, Sci Rep) - "Higher IgG-N levels prior to immunization, compared to pre-pandemic levels, suggest that prior exposure to circulating SARS-CoV-2 VoCs (other than Wuhan-Hu) in Malaysia shaped immune imprinting, influencing responses before immunization with the Wuhan-Hu-based vaccine. Consequently, this study reports higher IgG-S and NAb levels against VoCs-except Omicron-compared to Wuhan-Hu after COVID-19 vaccination."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases